Loading
When, after pre-surgery treatment, the removed tumour contains little or no living cancer: 10% or less viable cells.
Defined by the International Neoadjuvant Melanoma Consortium as ≤10% viable tumour (pathological complete response is 0%). In NADINA and earlier OpCACI trials, MPR predicted very low relapse risk and was used to decide whether adjuvant therapy could be omitted. The melanoma analogue of pCR in breast cancer.
Shares NADINA, Use pre-surgery immunotherapy windows as the field's biomarker engine, Treat the draining lymph node before removing it, Stage III melanoma (after surgery).
Shares Neoadjuvant immunotherapy → response-adapted adjuvant, Stage III melanoma (after surgery), Neoadjuvant / adjuvant / perioperative, Melanoma.
Shares NADINA, Stage III melanoma (after surgery), Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative.
Shares Use pre-surgery immunotherapy windows as the field's biomarker engine, Pathologic complete response (pCR), Neoadjuvant / adjuvant / perioperative, Resectable stage I to III non-small-cell lung cancer.
Shares Treat the draining lymph node before removing it, Stage III melanoma (after surgery), Neoadjuvant / adjuvant / perioperative, Melanoma.
Shares Neotorch, Neoadjuvant / adjuvant / perioperative, Resectable stage I to III non-small-cell lung cancer, Lung cancer (all types).
Shares NADINA, Stage III melanoma (after surgery), Melanoma.
Shares Treat the draining lymph node before removing it, Stage III melanoma (after surgery), Melanoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/